Research ArticleCase Reports

Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone

JEROME H. CHECK, DIANE L. CHECK and NAOMI GANPO-NKEWNKWA
Anticancer Research February 2026, 46 (2) 1153-1165; DOI: https://doi.org/10.21873/anticanres.18018

Article Information

vol. 46 no. 2 1153-1165
DOI 
https://doi.org/10.21873/anticanres.18018
PMID 
41617454
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received October 30, 2025
  • Revision received November 13, 2025
  • Accepted December 3, 2025
  • Published online January 30, 2026.
Copyright & Usage 
Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. JEROME H. CHECK1,2⇑,
  2. DIANE L. CHECK2 and
  3. NAOMI GANPO-NKEWNKWA1
  1. 1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cooper Medical School, Rowan University, Camden, NJ, U.S.A.;
  2. 2Cooper Institute for Reproductive Hormonal Disorders, Mt Laurel, NJ, U.S.A.
  1. Jerome H. Check, MD, PhD, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cooper Medical School, Rowan University, 401 Broadway, Camden, NJ, 08103, U.S.A. E-mail: megan.oneil{at}ccivf.com
View Full Text

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone
JEROME H. CHECK, DIANE L. CHECK, NAOMI GANPO-NKEWNKWA
Anticancer Research Feb 2026, 46 (2) 1153-1165; DOI: 10.21873/anticanres.18018
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords